Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
Results from the phase 3 FABULOUS trial demonstrated that the addition of apatinib to fuzuloparib significantly improved progression-free survival compared with fuzuloparib monotherapy or standard chemotherapy among patients with...
Results from the phase 3 FABULOUS trial demonstrated that the addition of apatinib to fuzuloparib significantly improved progression-free survival compared with fuzuloparib monotherapy or standard chemotherapy among patients with...
Sacituzumab govitecan prolongs progression-free survival vs standard chemotherapy among previously untreated patients with locally advanced, unresectable or metastatic triple-negative breast cancer unable to undergo PD-1/PD-L1 inhibition,...
Sacituzumab govitecan prolongs progression-free survival vs standard chemotherapy among previously untreated patients with locally advanced, unresectable or metastatic triple-negative breast cancer unable to undergo PD-1/PD-L1 inhibition,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Results from the phase 3 ASCENT-03 trial show that sacituzumab govitecan significantly improved efficacy and safety compared with standard chemotherapy among previously untreated patients with metastatic triple-negative breast cancer unable...
Results from the phase 3 ASCENT-03 trial show that sacituzumab govitecan significantly improved efficacy and safety compared with standard chemotherapy among previously untreated patients with metastatic triple-negative breast cancer unable...
According to results from the BEGONIA study, first-line datopotamab deruxtecan plus durvalumab demonstrated clinical promise among patients with advanced or metastatic triple-negative breast cancer.
According to results from the BEGONIA study, first-line datopotamab deruxtecan plus durvalumab demonstrated clinical promise among patients with advanced or metastatic triple-negative breast cancer.
Extended follow-up results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment continued to prolong survival among patients with HR-positive, HER2-negative early breast...
Extended follow-up results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment continued to prolong survival among patients with HR-positive, HER2-negative early breast...
A retrospective study found a positive correlation between MYB gene abnormalities and HER2 status among patients with mammary adenoid cystic carcinoma.
A retrospective study found a positive correlation between MYB gene abnormalities and HER2 status among patients with mammary adenoid cystic carcinoma.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
